ClinicalTrials.gg
Not yet recruitingNCT07147855Updated Sep 8, 2025

A Feasibility Mixed Methods Study of the Intervention Take Your Sexuality Back for Sexually Traumatized Women.

An interventional study of Take your sexuality back in Posttraumatic Stress Symptoms, Sexual Abuse and Sexual Trauma, sponsored by Sykehuset Telemark. Not yet recruiting at 1 site in Norway. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Sykehuset Telemark · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This study looks at the potential effects of a new group treatment called "Take Your Sexuality Back", designed for women who have experienced sexual trauma. Investigators will collect information in two ways-through forms that participants fill out themselves and through ECG measurements during a stress tests. Data will be collected before the treatment, right after it, and again three months later. When all data are collected and analyzed investigators will carry out in-depth interviews with participants and explore how they felt about being tested and how they understand the results -especially if some numbers look unusual or surprising. The goal with this study is to create a strong foundation for a future larger-scale study of the treatment by testing the methods, estimating the size of possible effects and identify outcome measurements that are experienced as meaningful to the participants.

02

Conditions studied

  • Posttraumatic Stress Symptoms
  • Sexual Abuse
  • Sexual Trauma

Browse trials for

03

In context

Sexual Trauma

14 studies on the registry are indexed under Sexual Trauma; 6 are open to participants now.

This study's planned enrollment of 20 is below the median of 26 across 12 interventional studies indexed under Sexual Trauma.

Browse Sexual Trauma studies →

Lead sponsor

Sykehuset Telemark is the lead sponsor of 33 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A history of sexual trauma.
  2. Experience trauma-related sexual problems.
  3. Age between 18 and 65 years.
  4. Enough competence in Norwegian to participate in a psychoeducational group.

Exclusion criteria

Exclusion Criteria:

  1. Acute suicidality.
  2. Serious substance abuse interfering with treatment
  3. Severe dissociative or psychotic disorders.
  4. Current life crisis interfering with treatment.
  5. Living in an abusive relationship. -
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment group "Take your sexuality back"

    A 12 week group intervention

    Behavioral: Take your sexuality back

Interventions

  • BehavioralTake your sexuality back

    A 12 weeks group program.

06

What researchers measure

Primary outcomes

  1. PTSD-symptoms and complex PTSD symptoms

    The international trauma questionnaire (ITQ). Zero (0) is equivalent to nothing and 4 indicates extremely. Higher scores mean worse outcome.

    Time frame: From enrollment to 3 month after end of treatment (12 weeks treatment)

  2. Sexual satisfaction

    The Sexual Satisfaction Scale for women (SSS-W). Different Likert scales. Higher scores mean worse outcome. Higher scores mean better outcome.

    Time frame: From enrollment to 3 months after end of treatment (12 weeks intervention)

  3. Sexual shame

    The Sexual shame index-revised (SSI-R). One (1) is equivalent to strongly disagree and 6 indicates strongly agree. Higher scores mean worse outcome.

    Time frame: From enrollment to 3 months after end of treatment (12 weeks intervention).

  4. Interoceptive awareness

    The Multidimensional Assessment of Interoceptive Awareness (MAYA 2). Zero is equivalent with never and 5 indicates always. Higher scores mean better outcome.

    Time frame: From enrollment to 3 months after end of treatment (12 weeks intervention).

  5. Responses to script-driven imagery.

    The Responses to script-driven imagery (RSDI) measures emotional, cognitive, and physiological responses in the script-driven imagery procedure. Zero is equivalent to "not at all" and six (6) indicates "very much". Higher scores mean worse outcome.

    Time frame: From enrollment to 3 months after end of treatment (12 weeks intervention).

  6. Touch body map

    Touch Body Map is an instrument for mapping how the body reacts to touch. Participants color the outlines of a human figure with three colors to mark how different areas of the body react to touch form a loved one. The body map gives a non-verbal expression of how trauma is embodied. The percentage of the different colors will be calculated to assess possible changes through the process

    Time frame: From enrollment to 3 months after end of the treatment (12 weeks intervention).

  7. Change in HRV and SampEn from pre-post and at follow up efter 3 month.

    Cardiovascular measurement (ECG) recorded during a script-driven imagery (SDI). HRV and SampEn.

    Time frame: Enrollment to 3 months after end of treatment (12 weeks intervention).

  8. Participants experiences of being tested and their understanding of the results.

    In-depth interviews with focus on participants own experiences and understanding og the quantitative results.

    Time frame: Three month after end of treatment, when all quantitative results are analyzed and calculated.

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data are sensitive and participants' anonymity cannot be guaranteed.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Sep 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Aug 29, 2025
StartEst.
Sep 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2027
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07147855
Lead sponsor
Sykehuset Telemark
Collaborators
University of Agder, Norwegian University of Science and Technology
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Sep 2025 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 8, 2025

Study contacts

Idun Røseth, PhD
Contact
IDUROE@sthf.no
0047-41200462
Siv Åshild Billington
Contact
Siv.Ashild.Billington@sthf.no
0047-97777857
Hege Kersten, PhD
study director · Research and Innovation Manager

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion